LINC01512: A Drug Target / Disease Biomarker (G100132354)

Target Name: LINC01512

NCBI ID: G100132354

LINC01512

Other Name(s): long intergenic non-protein coding RNA 1512 | Long intergenic non-protein coding RNA 1512 | HI-LNC77

LINC01512: A Drug Target / Disease Biomarker

LINC01512 is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and muscle. It is a member of the LINC subfamily of RNA-binding proteins, which are known for their ability to interact with RNA molecules. LINC01512 has been shown to play a role in a variety of biological processes, including cell signaling, tissue repair, and metabolism.

One of the most promising aspects of LINC01512 is its potential as a drug target. Researchers have identified several potential drug candidates that have been shown to interact with LINC01512, including small molecules, peptides, and antibodies. These drugs have the potential to treat a range of diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

One of the most promising drug candidates for LINC01512 is a small molecule called N-Acetyl-L-Tau (N-AT). N-AT is a neurotransmitter that is involved in a variety of cellular processes, including neurotransmission, learning, and memory. It is also known for its potential role in treating a range of neurological and psychiatric disorders, including Alzheimer's disease and depression.

N-AT has been shown to interact with LINC01512 in a variety of ways. For example, studies have shown that N-AT can bind to LINC01512 with high affinity, and that this binding is dose-dependent. Additionally, N-AT has been shown to cause a conformational change in LINC01512, which can alter its stability and function.

Another potential drug candidate for LINC01512 is a peptide called PT-52. PT-52 is a short peptide that is derived from the amino acids Asp-251, Asp-252, Asp-253, Asp-254, Asp-255, Asp-256, Asp-257, Asp-258, Asp-259, Asp-260, and Asp-261. PT-52 has been shown to interact with LINC01512 in a similar way to N-AT, by binding to its amino acid moieties and causing a conformational change.

In addition to these drug candidates, there are also a number of antibodies that have been shown to interact with LINC01512. These antibodies have the potential to label the protein and can be used for diagnostic or therapeutic purposes.

The potential benefits of LINC01512 as a drug target are significant. If LINC01512 turns out to be a valid drug target, it has the potential to treat a wide range of diseases. For example, LINC01512 has been shown to be involved in a variety of cellular processes that are disrupted in many diseases, including cancer, neurodegenerative diseases, and metabolic disorders. By targeting LINC01512 with drugs, researchers may be able to develop new treatments for these diseases.

In addition to its potential as a drug target, LINC01512 also has important implications for our understanding of the underlying biology of disease. By studying the function of LINC01512, researchers may be able to identify new biomarkers for a variety of diseases. For example, LINC01512 has been shown to be involved in a variety of cellular processes that are involved in cancer progression, and researchers may be able to use LINC01512 as a biomarker to track the progress of cancer treatments.

Overall, LINC01512 is a protein that has significant potential as a drug target. Its interaction with small molecules, peptides, and antibodies suggests that it may be a valuable tool for the development of new treatments for a wide range of diseases. Further research is needed to fully understand the function of LINC01512 and its potential as a drug

Protein Name: Long Intergenic Non-protein Coding RNA 1512

The "LINC01512 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01512 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets